🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Cancer Gene Mutation

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites📍 Akita📍 Sapporo📍 Suita-shi Enliven Therapeutics · Tests: ELVN-001 Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site📍 Busan Pusan National University Hospital · Tests: Local Therapy (Surgery or Radiotherapy) A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Germinal BRCA A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site📍 Shanghai Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH276, GFS202A Duodenal Polyposis Classification in FAP NCT07199127n/a2 sites📍 Milan📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: DRACO A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms NCT06034002Phase 113 sites📍 Duarte📍 Palo Alto📍 Miami Incyte Corporation · Tests: INCA033989, Ruxolitinib A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650Phase 3330 sites📍 Tucson📍 Irvine📍 Los Angeles Merck Sharp & Dohme LLC · Tests: Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410Phase 337 sites📍 Hefei📍 Beijing📍 Beijing Allist Pharmaceuticals, Inc. · Tests: JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342Phase 23 sites📍 Beijing📍 Guangzhou📍 Zhejiang Jianxing He · Tests: fulzerasib Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations NCT07143669n/a26 sites📍 Birmingham📍 Birmingham📍 Scottsdale Blueprint Medicines Corporation · Tests: Screening A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer NCT07532434n/a1 site📍 Beijing Peking University Third Hospital CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04493164Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation NCT06898385Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: IX001 TCR-T injection, Fludarabine, Cyclophosphamide Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma NCT05528458Phase 21 site📍 Seoul Samsung Medical Center · Tests: Osimertinib 80Mg Tab TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer NCT04740697NA1 site📍 Toulouse Institut Claudius Regaud · Tests: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen. Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer NCT06441110Phase 31 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: Tislelizumab in Combination with Bacillus Calmette-Guérin An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results NCT05420064NA8 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation NCT06102928NA1 site📍 Kunming Kunming Medical University · Tests: Combined therapy of anlotinib and aumolertinib Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers NCT06408402n/a20 sites📍 Angers📍 Besançon📍 Bron Assistance Publique - Hôpitaux de Paris Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour NCT06383871Phase 11 site📍 Tianjin Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-7058 capsule/ HRS-7058 tablet Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan NCT06358222n/a1 site📍 Shanghai Shanghai Chest Hospital · Tests: Blood ctDNA + methylation + PET-CT and Postoperative pathology, MRD+ methylation (or combined with PET-CT) and Invasive… A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms NCT07849231Phase 136 sites📍 Birmingham📍 Gilbert📍 Duarte Damora Therapeutics · Tests: DMR-001, Ruxolitinib DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy